Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks
Statistically significant improvements in efficacy were observed as early as 2 weeks
Primary endpoint met with no serious adverse events observed
LYR-220, Lyra’s second product candidate, is a long-acting anti-inflammatory therapy in development for CRS patients with and without polyps who have recurrent symptoms despite prior ethmoid sinus surgery
Conference call today at 8:00 a.m. ET.
Lyra will host a conference call and webcast on Tuesday, September 12 at 8:00 a.m. ET to discuss the topline results of the BEACON study.
To listen online via webcast, please visit: https://edge.media-server.com/mmc/p/xfx5b2kt. The webcast and accompanying slides will be archived and available at https://investors.lyratherapeutics.com.
To participate in the conference call by telephone, please register using this online form: https://register.vevent.com/register/BI5027ff27ec2f477cb5cdb98957d840d2.
https://finance.yahoo.com/news/lyra-therapeutics-announces-positive-topline-110000415.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.